Camerini A, Griffo R
Ital Heart J Suppl. 2001 Jan;2(1):1-6.
The role of digitalis in the treatment of patients with heart failure is still being debated. The DIG study, a trial which enrolled about 6800 patients with the aim at overcoming the doubts on efficiency and safety of digoxin, showed a neutral effect on mortality but there was a statistically significant decreased risk of hospitalization due to worsening heart failure in the digoxin group compared to the placebo group. The trial disclosed several problems about patient selection (many patients were on digitalis before the start of the trial), digoxin dosage, which seemed to be high, and about the true reported beneficial effects of this therapy. Finally the data available do not permit any evaluation on the use of beta-blockers and the association between digitalis and beta-blockers considering the properties of these drugs in suppressing orthosympathetic activation.
洋地黄在心力衰竭患者治疗中的作用仍存在争议。地高辛干预研究（DIG研究）纳入了约6800例患者，旨在消除对洋地黄疗效和安全性的疑虑，该研究显示其对死亡率呈中性影响，但与安慰剂组相比，地高辛组因心力衰竭恶化导致的住院风险有统计学意义的降低。该试验暴露出几个问题，包括患者选择（许多患者在试验开始前就已使用洋地黄）、地高辛剂量似乎偏高，以及这种疗法真正报道的有益效果。最后，鉴于β受体阻滞剂在抑制交感神经激活方面的特性，现有数据无法对其使用以及洋地黄与β受体阻滞剂的联合应用进行任何评估。
